Cargando…

Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review

STUDY BACKGROUND OBJECTIVES: Cancer poses a significant health concern as it is incurable. Every year, research on how to treat and eradicate this chronic condition is done. This systematic review will unmask the recent developments concerning highly active 1C metabolism with regard to cancer diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuang, Wang, Zheng-Miao, Lv, Dong-Mei, Zhao, Yi-Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751587/
https://www.ncbi.nlm.nih.gov/pubmed/36531038
http://dx.doi.org/10.3389/fonc.2022.1063305
_version_ 1784850507909562368
author Liu, Shuang
Wang, Zheng-Miao
Lv, Dong-Mei
Zhao, Yi-Xuan
author_facet Liu, Shuang
Wang, Zheng-Miao
Lv, Dong-Mei
Zhao, Yi-Xuan
author_sort Liu, Shuang
collection PubMed
description STUDY BACKGROUND OBJECTIVES: Cancer poses a significant health concern as it is incurable. Every year, research on how to treat and eradicate this chronic condition is done. This systematic review will unmask the recent developments concerning highly active 1C metabolism with regard to cancer diagnosis, treatment, and drug resistance. The significance of this study is rolling out evidence-based evidence on the importance of one-carbon metabolism in cancer diagnosis and treatment. METHODS: Eight randomized controlled trials (RCTs) were reviewed from five electronic databases – EMBASE, Scopus Review, Google Scholar, Web of Science, and PubMed. Outcomes from the eight studies were analyzed to paint a picture of the topic in question. While the Preferred Reporting Items for Systematic Reviews and Meta-Analysis’ (PRISMA) protocol guided the initial literature search, The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach informed quality assessments of the eligible studies. CONCLUSION: Since its emergence in the 1980s, 1C metabolism has been investigated and broadened to capture essential aspects of cancer treatment, diagnosis, and drug resistance. The review found that metabolites like folic acid could be used to detect different types of cancer. The metabolic pathways could induce tumorigenesis and DNA methylation, hence drug resistance. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/projects/, identifier INPLASY2022110099.
format Online
Article
Text
id pubmed-9751587
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97515872022-12-16 Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review Liu, Shuang Wang, Zheng-Miao Lv, Dong-Mei Zhao, Yi-Xuan Front Oncol Oncology STUDY BACKGROUND OBJECTIVES: Cancer poses a significant health concern as it is incurable. Every year, research on how to treat and eradicate this chronic condition is done. This systematic review will unmask the recent developments concerning highly active 1C metabolism with regard to cancer diagnosis, treatment, and drug resistance. The significance of this study is rolling out evidence-based evidence on the importance of one-carbon metabolism in cancer diagnosis and treatment. METHODS: Eight randomized controlled trials (RCTs) were reviewed from five electronic databases – EMBASE, Scopus Review, Google Scholar, Web of Science, and PubMed. Outcomes from the eight studies were analyzed to paint a picture of the topic in question. While the Preferred Reporting Items for Systematic Reviews and Meta-Analysis’ (PRISMA) protocol guided the initial literature search, The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach informed quality assessments of the eligible studies. CONCLUSION: Since its emergence in the 1980s, 1C metabolism has been investigated and broadened to capture essential aspects of cancer treatment, diagnosis, and drug resistance. The review found that metabolites like folic acid could be used to detect different types of cancer. The metabolic pathways could induce tumorigenesis and DNA methylation, hence drug resistance. SYSTEMATIC REVIEW REGISTRATION: https://inplasy.com/projects/, identifier INPLASY2022110099. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751587/ /pubmed/36531038 http://dx.doi.org/10.3389/fonc.2022.1063305 Text en Copyright © 2022 Liu, Wang, Lv and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Shuang
Wang, Zheng-Miao
Lv, Dong-Mei
Zhao, Yi-Xuan
Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title_full Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title_fullStr Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title_full_unstemmed Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title_short Advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: A systematic review
title_sort advances in highly active one-carbon metabolism in cancer diagnosis, treatment and drug resistance: a systematic review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751587/
https://www.ncbi.nlm.nih.gov/pubmed/36531038
http://dx.doi.org/10.3389/fonc.2022.1063305
work_keys_str_mv AT liushuang advancesinhighlyactiveonecarbonmetabolismincancerdiagnosistreatmentanddrugresistanceasystematicreview
AT wangzhengmiao advancesinhighlyactiveonecarbonmetabolismincancerdiagnosistreatmentanddrugresistanceasystematicreview
AT lvdongmei advancesinhighlyactiveonecarbonmetabolismincancerdiagnosistreatmentanddrugresistanceasystematicreview
AT zhaoyixuan advancesinhighlyactiveonecarbonmetabolismincancerdiagnosistreatmentanddrugresistanceasystematicreview